This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aboudola, S.
Right arrow Articles by Kelly, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aboudola, S.
Right arrow Articles by Kelly, C. P.

 Previous Article  |  Next Article 

Infection and Immunity, March 2003, p. 1608-1610, Vol. 71, No. 3
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.3.1608-1610.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A

Samer Aboudola,1 Karen L. Kotloff,2* Lorraine Kyne,3 Michel Warny,4 Eoin C. Kelly,1 Stavros Sougioultzis,1 Paul J. Giannasca,4 Thomas P. Monath,4 and Ciarán P. Kelly1

Gastroenterology,1 Gerontology Divisions, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,3 Acambis, Inc., Cambridge, Massachusetts,4 Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland2

Received 27 August 2002/ Returned for modification 3 October 2002/ Accepted 21 November 2002

There is a strong association between serum antibody responses to toxin A and protection against Clostridium difficile diarrhea. A parenteral C. difficile toxoid vaccine induced very-high-level responses to anti-toxin A immunoglobulin G (IgG) in the sera of healthy volunteers. After vaccination, the concentrations of anti-toxin A IgG in the sera of all 30 recipients exceeded the concentrations that were associated with protection in previous clinical studies. Furthermore, the median concentration of serum anti-toxin A IgG in the test group was 50-fold higher than the previous threshold. These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis.

* Corresponding author. Mailing address: Center for Vaccine Development, University of Maryland School of Medicine, 685 W. Baltimore St., HSF 480, Baltimore, MD 21201. Phone: (410) 706-5328. Fax: (410) 706-6205. E-mail: kkotloff{at}medicine.umaryland.edu.

Editor: J. T. Barbieri

Infection and Immunity, March 2003, p. 1608-1610, Vol. 71, No. 3
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.3.1608-1610.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kelly, C. P. (2009). A 76-Year-Old Man With Recurrent Clostridium difficile-Associated Diarrhea: Review of C difficile Infection. JAMA 301: 954-962 [Abstract] [Full Text]  
  • Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]  
  • Cross, A. S., Chen, W. H., Levine, M. M. (2008). A case for immunization against nosocomial infections. J. Leukoc. Biol. 83: 483-488 [Abstract] [Full Text]  
  • Chandrasekar, T, Naqvi, N, Waddington, A, Cooke, R., Anijeet, H., Gradden, C., Abraham, K., Wong, C. (2008). Intravenous immunoglobulin therapy for refractory Clostridium difficile toxin colitis in chronic kidney disease: case reports and literature review. NDT Plus 1: 20-22 [Full Text]  
  • Ghose, C., Kalsy, A., Sheikh, A., Rollenhagen, J., John, M., Young, J., Rollins, S. M., Qadri, F., Calderwood, S. B., Kelly, C. P., Ryan, E. T. (2007). Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice. Infect. Immun. 75: 2826-2832 [Abstract] [Full Text]  
  • Jodlowski, T. Z, Oehler, R., Kam, L. W, Melnychuk, I. (2006). Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2164-2169 [Abstract] [Full Text]  
  • Pechine, S., Janoir, C., Collignon, A. (2005). Variability of Clostridium difficile Surface Proteins and Specific Serum Antibody Response in Patients with Clostridium difficile-Associated Disease. J. Clin. Microbiol. 43: 5018-5025 [Abstract] [Full Text]  
  • Tonna, I, Welsby, P D (2005). Pathogenesis and treatment of Clostridium difficile infection. Postgrad. Med. J. 81: 367-369 [Abstract] [Full Text]  
  • Voth, D. E., Ballard, J. D. (2005). Clostridium difficile Toxins: Mechanism of Action and Role in Disease. Clin. Microbiol. Rev. 18: 247-263 [Abstract] [Full Text]  
  • Wilcox, M. H. (2004). Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53: 882-884 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»